Category: Press Releases

Genprex Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month

Genprex published lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness of lung cancer while supporting November’s Lung Cancer Awareness Month.

Read More

Genprex to Present at the MicroCap Rodeo Investor Conference

Genprex will present in Austin, Texas on Tuesday, October 15 at 9:10 a.m. CDT.

Read More

Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support

Additional research is being done in the field that validates non-viral vector delivery as the next evolution in gene therapy.

Read More

Genprex to Present Via Webcast at the Singular Research Midwestern Values Conference on September 19, 2019

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company's webcast presentation.

Read More

Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer

Independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC).

Read More

Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company's presentation on September 9, 2019 in New York City.

Read More

Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck

These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found at Genprex.com.

Read More

Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference

Genprex's Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference in New York City on September 4, 2019.

Read More

Genprex Demonstrates Growth and Expansion Through Recent Achievements

Company’s recent performance sets path for future milestones, commercialization

Read More

Genprex Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program

Genprex's newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies.

Read More